反应方程式
[N:1]1[C:10]2[C:5](=[CH:6][CH:7]=[CH:8][CH:9]=2)[CH:4]=[C:3]([CH:11]=O)[CH:2]=1.[NH2:13][C:14]1[CH:15]=[C:16]2[C:20]3=[C:21]([CH2:23][S:24][CH2:25][CH2:26][N:19]3[C@H:18]3[CH2:27][CH2:28][N:29](C(OC(C)(C)C)=O)[CH2:30][C@@H:17]23)[CH:22]=1>>[N:1]1[C:10]2[C:5](=[CH:6][CH:7]=[CH:8][CH:9]=2)[CH:4]=[C:3]([CH2:11][NH:13][C:14]2[CH:15]=[C:16]3[C:20]4=[C:21]([CH2:23][S:24][CH2:25][CH2:26][N:19]4[C@H:18]4[CH2:27][CH2:28][NH:29][CH2:30][C@@H:17]34)[CH:22]=2)[CH:2]=1参与物
3
实验过程
Using 3-quinolinecarboxaldehyde and following the procedures described in EXAMPLE 126, tert-butyl (7bR,11aS)-6-amino-1,2,7b,10,11,11a-hexahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indole-9(8H)-carboxylate from EXAMPLE 33, Part B was converted into the title compound of EXAMPLE 164. LRMS (ES)+: 403.4 (M+H)+.
来源与证据
- ORD记录
- ord-54cbc3c9aa1a4abb89a40d04e35c3eb8
- 来源数据集
- uspto-grants-2004_03
- 专利号
- US06699852B2
关联笔记
加载中…